Physician profile
Olin M Fox
NPI 1659379600
$1,949.07
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,935 · 2020: $13.76.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $354.02 | 2019 | |
| Alkermes, INC. | $318.30 | 2019 | |
| Allergan, INC. | $224.62 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $142.85 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $134.16 | 2019 | |
| Shire North American Group INC | $117.03 | 2019 | |
| Indivior INC. | $108.60 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.35 | 2019 | |
| Janssen Pharmaceuticals, INC | $90.24 | 2019 | |
| Neurocrine Biosciences, INC. | $82.10 | 2019 | |
| Ironshore Pharmaceuticals INC. | $62.68 | 2019 | |
| Avanir Pharmaceuticals, INC. | $52.24 | 2019 | |
| Vanda Pharmaceuticals INC. | $47.51 | 2019 | |
| Lundbeck LLC | $34.41 | 2019 | |
| Arbor Pharmaceuticals, INC. | $27.92 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $24.39 | 2019 | |
| Neuronetics, INC. | $13.31 | 2019 | |
| Acadia Pharmaceuticals INC | $11.34 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olin Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.